PTJ
REGN icon

Paul Tudor Jones’s Regeneron Pharmaceuticals REGN Stock Holding History

Paul Tudor Jones’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-700
Closed -$541K – 4152
2026
Q1 		$541K Sell
700
-51,500
-99% -$39.4M ﹤0.01% 2762
2025
Q4 		$40.3M Buy
52,200
+22,600
+76% +$15.3M 0.07% 204
2025
Q3 		$16.6M Buy
29,600
+1,100
+4% +$622K 0.03% 522
2025
Q2 		$15M Sell
28,500
-4,700
-14% -$2.62M 0.03% 465
2025
Q1 		$21.1M Buy
33,200
+23,200
+232% +$16M 0.07% 202
2024
Q4 		$7.12M Buy
10,000
+6,900
+223% +$5.79M 0.03% 510
2024
Q3 		$3.26M Buy
+3,100
New +$3.45M 0.01% 928

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Paul Tudor Jones's REGN Position: Q3 2025 in Review

Paul Tudor Jones sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 84,550 shares — an estimated $47.8M sold.

Paul Tudor Jones first reported a position in REGN in Q2 2013 and held it in 26 quarters. The position peaked at $80M in Q1 2025. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Paul Tudor Jones reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Paul Tudor Jones sold 84,550 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $47.8M.
  • Paul Tudor Jones first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 26 quarters.
  • Paul Tudor Jones's Regeneron Pharmaceuticals position peaked at $80M in Q1 2025.
  • 1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Tudor Investment Corp's 13F filing for Q3 2025, filed 14 Nov 2025.